Ammoxetine vs Duloxetine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: Serotonin/norepinephrine transporter · full Major Depressive Disorder pipeline

Ammoxetine

Developed by CSPC Pharmaceutical Group

Phase 3 in Major Depressive Disordersmall molecule
Partial signal

NCT06827431 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 770 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8) (From baseline to Week 8): Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27). (met)

Result source: NCT06827431

Duloxetine · Cymbalta

Marketed by Eli Lilly

Approved in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmmoxetineDuloxetine
MADRS, change (acute)—Not posted · NCT06827431—Not posted · NCT00036309
CGI-S, change (acute)—Not posted · NCT06827431—Not posted · NCT00036309
MADRS response—Not posted · NCT06827431—Not posted · NCT00036309
MADRS remission—Not posted · NCT06827431—Not posted · NCT00036309
Relapse (% of patients)—Not posted · NCT06827431—Not posted · NCT00036309

MADRS, change (acute)

Ammoxetine
—Not posted · NCT06827431
Duloxetine
—Not posted · NCT00036309

CGI-S, change (acute)

Ammoxetine
—Not posted · NCT06827431
Duloxetine
—Not posted · NCT00036309

MADRS response

Ammoxetine
—Not posted · NCT06827431
Duloxetine
—Not posted · NCT00036309

MADRS remission

Ammoxetine
—Not posted · NCT06827431
Duloxetine
—Not posted · NCT00036309

Relapse (% of patients)

Ammoxetine
—Not posted · NCT06827431
Duloxetine
—Not posted · NCT00036309
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Duloxetine: registry results are on file for Major Depressive Disorder, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ammoxetine
Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27). NCT06827431 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ammoxetine's landscape · Duloxetine's landscape